Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision: v3.4.3 has been added, and Revision: v3.4.2 has been removed.SummaryDifference0.1%

- Check54 days agoChange DetectedThe update includes a minor site-version revision (Revision: v3.4.2) and removal of a government-operating-status notice; no study content, eligibility criteria, or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedA government funding lapse notice was added and the revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check68 days agoChange DetectedUI and metadata updates were applied: a 'Show glossary' toggle is now shown, and QC-related labels were updated to 'Last Update Submitted that Met QC Criteria' with a new 'Revision: v3.4.0'. The 'No FEAR Act Data' label is present and older variant labels were removed.SummaryDifference0.2%

- Check82 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.4', replacing the previous 'v3.3.3', with no observed changes to core content, eligibility criteria, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.